Overcoming Ovarian Cancer Chemoresistance Cancer Sensitizing Agents for Chemotherapy Series
Coordonnateurs : Samimi Goli, Annunziata Christina
Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment.
The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future.
This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer.
Dr Annunziata is Principal Investigator and Clinical Director of the Women’s Malignancies Branch at the National Cancer Institute in Bethesda, Maryland. She received her MD and PhD from Georgetown University, and completed residency in Internal Medicine at that institution, followed by Medical Oncology Fellowship at the NCI. In the Intramural Program of the NCI, she runs a translational research laboratory and is involved with several clinical protocols. She has mentored both scientific and clinical fellows, who moved on to Assistant Professor positions, with independent grant funding. Outside the NIH, Dr. Annunziata has chaired grant review committees for ASCO and DOD.
- Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response
- Discusses genetic reversions as a unique alteration and a new field of study
- Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field
Date de parution : 11-2020
Ouvrage de 188 p.
19x23.3 cm
Thème d’Overcoming Ovarian Cancer Chemoresistance :
Mots-clés :
Aggregation; Antiangiogenesis; Beta tubulin; BRAF inhibitors; BRCA1; BRCA2; Breast cancer; Cancer immunotherapy; Cancer stem cells; CAR-T cell; Cell lines; Chemoresistance; Chemotherapy; Chemotherapy resistance; Clinical trials; Copper transporters; Denosumab; Differentiation; DNA repair; Drug resistance; Egg-laying hen model; Genetically engineered mouse models; High-grade serous ovarian cancer; Homologous recombination repair; IDO; Immune checkpoint inhibitor; Immunotherapy; MDR; MEK inhibitors; Multicellular aggregate/spheroid models; Novel agents; NY-ESO-1; Organoids; Ovarian cancer; Ovarian carcinoma; p53 mutation; p53 reactivation; PARP inhibitors; PD-1; Phenotypic heterogeneity; Platinum agents; Platinum-based chemotherapy; Prevention; Proliferation; Recurrence; Reversion mutation; Syngeneic models; T cell trafficking; Targeted treatment; Taxanes; Tumor antigens; Tumor initiation; Tumor microenvironment; Xenograft models
